Response to Immune Checkpoint Antibodies: Not All Responses Are Created Equal.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30510039.
- Also identified by DOI 10.1158/1078-0432.CCR-18-3296.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Early reports from immunotherapy trials conclude durable responses. Long-term data may indicate otherwise. Better delineation of clinical courses of long-term survivors will accelerate the discovery and application of biomarkers. Two pressing issues among those treated with anti-PD-1/PD-L1 are understanding whether responders can have therapy abbreviated and overcoming resistance in nonresponders.<i>See related article by Gauci et al., p. 946</i>.
Medical subject headings
- B7-H1 Antigen
- Programmed Cell Death 1 Receptor